Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 07, 2022

SELL
$2.87 - $6.29 $54,386 - $119,195
-18,950 Closed
0 $0
Q3 2021

Oct 19, 2021

SELL
$4.91 - $9.07 $69,722 - $128,794
-14,200 Reduced 42.84%
18,950 $118,000
Q2 2021

Jul 16, 2021

BUY
$7.82 - $13.8 $86,802 - $153,180
11,100 Added 50.34%
33,150 $282,000
Q1 2021

Apr 29, 2021

BUY
$13.0 - $19.34 $27,560 - $41,000
2,120 Added 10.64%
22,050 $338,000
Q4 2020

Jan 14, 2021

BUY
$13.03 - $17.09 $17,720 - $23,242
1,360 Added 7.32%
19,930 $322,000
Q3 2020

Oct 15, 2020

BUY
$12.67 - $23.19 $108,328 - $198,274
8,550 Added 85.33%
18,570 $259,000
Q2 2020

Jul 20, 2020

BUY
$12.52 - $23.45 $125,450 - $234,969
10,020 New
10,020 $213,000

Others Institutions Holding BCEL

About Atreca, Inc.


  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Vigilare Wealth Management Portfolio

Follow Vigilare Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vigilare Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Vigilare Wealth Management with notifications on news.